Metabolic / Incretin

Mazdutide

Also: IBI362 · LY3305677

Once-weekly GLP-1 and glucagon dual agonist for weight loss, approved in China in 2025.

Discussion

Overview

What it is

Developed by Innovent and Eli Lilly. Phase 3 trials in Chinese adults showed double-digit percentage weight loss over 48 weeks, along with lower liver fat and blood pressure.

Common forms

Weekly injection

Mechanism

How it works

Activates GLP-1 receptors (appetite and insulin) and glucagon receptors (energy use and liver fat burning).

GLP-1 receptor agonismGlucagon receptor agonismHepatic fat oxidation

↓Body weight

↓Liver fat

↓Appetite

Hormonal impact

↑Insulin

↑Glucagon signaling

Evidence

What the research supports

Weight loss in adults with overweight or obesitystrong

Reduces liver fatmoderate

Safety

Side effects & interactions

Side effects

Nausea
Diarrhea
Vomiting
Raised heart rate serious
Pancreatitis risk (class effect) serious

Medications

Insulin / sulfonylureasmoderateHigher risk of low blood sugar.

Stacking

Combines with

Pairs well

Nothing specific.

Avoid combining

Other GLP-1 drugsDuplicate therapy.

Community

Discussion

Experiences from people who have tried Mazdutide. Anecdotes are not medical advice.

Loading discussion…